Safety and Tolerability of MK-5720 in Treating Schizophrenia

Study Description

This study aims to assess the safety and tolerability of MK-5720 in individuals diagnosed with schizophrenia. The focus is on evaluating how the body processes the drug and ensuring it is well tolerated.

Study Details

Registry ID:

NCT05953740

Conditions:

Schizophrenia

Phase:

Phase 1

Target Enrollment:

17 participants

Start Date:

September 15, 2023

Age Range:

18–60 years

Healthy Volunteers:

No

Study Locations (4 sites)

• Velocity Clinical Research, Hallandale Beach ( Site 0002)
  Hallandale Beach, FloridaUnited States, United States
• Research Centers of America ( Hollywood ) ( Site 0001)
  Hollywood, FloridaUnited States, United States
• Hassman Research Institute Marlton Site ( Site 0007)
  Marlton, New JerseyUnited States, United States
• California Clinical Trials Medical Group managed by PAREXEL ( Site 0003)
  Glendale, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →